Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €453.42 EUR
Change Today -18.58 / -3.94%
Volume 8.0
RHPP On Other Exchanges
Symbol
Exchange
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 10:30 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

54, Rue La Boétie

Paris, 75008

France

Phone: 33 1 53 77 40 00

Fax: 33 1 53 77 42 96

f acute coronary syndrome (ACS) with and without ST segment elevation in combination with acetylsalicylic acid (ASA). Plavix is also available in a 300 mg tablet that reinforces early use by simplifying its approved loading dose administration in patients with ACS. Plavix is also indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events in atrial fibrillation (AF), including stroke. CoPlavix/DuoPlavin, a fixed dose combination of clopidogrel bisulfate and ASA, is indicated for the prevention of atherothrombotic events in adult patients with ACS who are already taking both clopidogrel and ASA. Generics are expected to launch in 2015 in Japan. Plavix is the major anti-platelet in the Chinese market. The main countries contributing to sales of Plavix/Iscover were Japan and China in 2014. Lovenox/Clexane: Lovenox (enoxaparin sodium) is registered for a range of clinical indications than any other low-molecular weight heparin. Its clinical dossier has demonstrated a favorable risk-benefit ratio, including in the prophylaxis and treatment of venous thromboembolism and in the treatment of ACS. In the prevention of venous thromboembolism, the use of Lovenox continues to improve, particularly in the area of prophylaxis of deep vein thrombosis in patients hospitalized for an acute medical condition. In the United States, three enoxaparin generics have been approved, as well as the company’s own Lovenox generic. In 2014, Lovenox was the major injectable anti-thrombotic in all European countries. Aprovel/Avapro/Karvea: Aprovel (irbesartan) is an anti-hypertensive belonging to the class of angiotensin II receptor antagonists. In addition to Aprovel/Avapro/Karvea, the company markets CoAprovel/Avalide/Karvezide, a fixed dose combination of irbesartan and hydrochlorothiazide, a diuretic that increases the excretion of water and sodium by the kidneys and provides an additional blood pressure lowering effect. Aprovel and CoAprovel tablets are available in a range of dosages to fit the needs of patients with different levels of hypertension severity. Aprovel is indicated as a first line treatment for hypertension and for the treatment of nephropathy in hypertensive patients with type 2 diabetes. CoAprovel is indicated in patients whose blood pressure is not adequately controlled with a monotherapy, but also as initial therapy in patients at high risk or with markedly high baseline BP or who are likely to need multiple drugs to achieve their blood pressure goals. Aprovel and CoAprovel are marketed in approximately 80 countries. The main countries contributing to sales of Aprovel/Avapro/Karvea were China and Japan in 2014. Renagel and Renvela: Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate) are oral phosphate binders used by chronic kidney disease (CKD) patients on dialysis, as well as late stage CKD patients in Europe to treat a condition called hyperphosphatemia, or elevated phosphorus levels, which is associated with heart and bone disease. Renvela is a second generation, buffered phosphate binder. Renagel and Renvela are marketed in approximately 80 countries. In Japan and various Pacific Rim countries, Renagel is marketed by Chugai Pharmaceutical Co., Ltd and its sublicensee, Kyowa Hakko Kirin Co., Ltd. The main countries contributing to sales of Renagel and Renvela were the United States, France, Italy, Brazil and the United Kingdom in 2014. Allegra/Telfast: Allegra (fexofenadine hydrochloride) is a long-lasting (12- and 24-hour) non-sedating prescription anti-histamine for the treatment of seasonal allergic rhinitis (hay fever) and uncomplicated hives. It offers patients significant relief from allergy symptoms without causing drowsiness. The company also markets Allegra-D 12 Hour and Allegra-D 24 Hour, anti-histamine/decongestant combination products with an extended-release decongestant for effective non-drowsy relief of seasonal allergy symptoms, including nasal congestion. Generics of various forms of Allegra/Tefast have been approved in its major markets. In the United States, the Allegra family moved to over-the- counter (OTC) use in adults and chi

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHPP:FP €453.42 EUR -18.58

RHPP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $163.58 USD -0.26
Bayer AG €137.36 EUR -0.25
Bristol-Myers Squibb Co $68.30 USD -0.59
GlaxoSmithKline PLC 1,465 GBp +14.00
Medtronic PLC $77.82 USD -0.59
View Industry Companies
 

Industry Analysis

RHPP

Industry Average

Valuation RHPP Industry Range
Price/Earnings 29.3x
Price/Sales 3.6x
Price/Book 2.2x
Price/Cash Flow 18.5x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-TITR PART10%87, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.